Skye Bioscience, Inc. Common Stock (SKYE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.83M
Last updated: Nov 17, 2026 at 4:10 PM ET
Skye Bioscience, Inc. Common Stock (SKYE) Statistics
Skye Bioscience, Inc. Common Stock (SKYE) has a market cap of $4.83M. It earned -$37.67M on revenue of $0 over the last 12 months.
Total Valuation
| Market Cap | $4.83M |
|---|---|
| Latest price (Nov 17, 2026) | $1.00 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 90.38% over 52 weeks and trades 34.21% below its 50-day average.
| Beta (1Y) | 0.61 |
|---|---|
| 52-Week Change | -90.38% |
| 1-Month Change | -34.64% |
| 3-Month Change | -59.14% |
| 6-Month Change | -82.76% |
| 5-Year Change | -99.11% |
| 10-Year Change | -99.90% |
| Total Return (1Y) | -90.38% |
| Total Return (3Y CAGR) | -58.42% |
| Total Return (5Y CAGR) | -61.89% |
| Return vs SPY (1Y) | -102.16% |
| Max Drawdown (1Y) | -93.84% |
| Max Drawdown (3Y) | -99.52% |
| Sharpe Ratio (1Y) | -2.34 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $1.52 |
| 200-Day Average | $4.44 |
| 52-Week Range | $0.26 to $2.25 |
| RSI (14 Days) | 37.6 |
| Average Volume (20 Days) | 122.95K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.36x current liabilities.
| Current Ratio | 1.36x |
|---|---|
| Quick Ratio | 1.36x |
Returns and Efficiency
Return on equity is -2768.93% and return on assets is -742.59% over the last 12 months.
| Return on Equity (ROE) | -2768.93% |
|---|---|
| Return on Assets (ROA) | -742.59% |
Scores
SKYE has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$43.60M |
| Pretax Income | -$37.67M |
| Net Income | -$37.67M |
| Reported EPS (TTM) | -$6.10 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 26.82% of the $5.07M in total assets.
| Cash and Equivalents | $4.82M |
|---|---|
| Working Capital | $1.32M |
| Shareholder Equity | $1.36M |
| Book Value Per Share | $0.27 |
| Total Assets | $5.07M |
| Total Liabilities | $3.71M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $9 of capital spending, operating cash flow left -$30.58M of free cash flow.
| Operating Cash Flow | -$30.58M |
|---|---|
| Capital Expenditures | $9 |
| Free Cash Flow | -$30.58M |
| FCF Per Share | -$6.91 |
| Depreciation and Amortization | $541.82K |
Trailing 12 months through Sep 30, 2026.
Stock Splits
The last split was a 1-for-8 reverse split on Aug 24, 2026.
| Last Split Date | Aug 24, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:8 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SKYE
What is SKYE's market cap?
Skye Bioscience, Inc. Common Stock has a market cap of $4.83M.
How many shares of SKYE are outstanding?
Skye Bioscience, Inc. Common Stock has 4.99M shares outstanding. The count is up 0.73% from a year earlier.
Does SKYE pay a dividend?
No. Skye Bioscience, Inc. Common Stock does not pay a dividend.
SKYE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors